Interventions for fatigue in peripheral neuropathy

Area of Science:

• Neurology
• Clinical Trials
• Evidence-Based Medicine

Background:

• Persistent subjective fatigue is a common and debilitating symptom in individuals with peripheral neuropathy.
• The efficacy and safety of various interventions for fatigue in this population are not well-established.

Purpose of the Study:

• To systematically assess the effects of pharmacological and non-pharmacological interventions for fatigue in adults and children diagnosed with peripheral neuropathy.

Main Methods:

• Conducted a comprehensive search of multiple electronic databases and trial registries up to November 2013.
• Included randomized controlled trials (RCTs) and quasi-RCTs evaluating interventions against placebo or no intervention.
• Independently extracted data and assessed risk of bias, collecting information on adverse events.

Main Results:

• One low-quality study on amantadine for Guillain-Barré syndrome (GBS) yielded uncertain results regarding fatigue improvement.
• Moderate-quality evidence from two studies suggests ascorbic acid provides minimal benefit for fatigue in Charcot-Marie-Tooth disease type 1A (CMT1A).
• No serious adverse events were reported for amantadine; ascorbic acid trials reported similar serious adverse event rates between treatment and placebo groups.

Conclusions:

• Amantadine's effects on fatigue in GBS are inconclusive.
• Ascorbic acid demonstrates limited meaningful benefit for fatigue in CMT1A.
• Limited data exist on adverse effects, but both interventions appear safe. Evidence for other fatigue interventions in peripheral neuropathy is lacking, necessitating further RCTs and cost-effectiveness analyses.